News Archive Navigation
icon
Showing 48 results
March 2021
-
Media ReleaseNovartis receives approval for Kymriah® (tisagenlecleucel) by Health Sciences Authority as Singapore’s first commercially approved CAR-T therapyKymriah, the first chimeric antigen receptor T-cell (CAR-T) therapy approved in Singapore, is indicated as a one-time treatment manufactured individually for each patient. Novartis works closely…
-
Media ReleaseNovartis Piqray® - First and only treatment specially for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer receives HSA approvalPiqray (alpelisib) is the only treatment approved specifically to address PIK3CA mutation The approval was based on SOLAR-1 Phase III trial showing Piqray plus fulvestrant nearly doubled median…
May 2020
-
In The NewsLeading without being "the boss": Novartis SG's Kevin Zou
-
Media ReleaseNovartis Singapore returns Job Support Scheme payout worth SGD3.7 Million; aids community efforts against COVID-19Novartis Singapore commits to no retrenchments due to the COVID-19 pandemic, returns SGD 3.7 million worth of Job Support Scheme (JSS) in April 2020 and declines any future payouts related to the…
-
Featured NewsSupporting our community during this pandemic
-
In The News新加坡区总裁邹澄:诺华集团要推动本地药剂生产数码化 提升运营效率